GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mangoceuticals Inc (NAS:MGRX) » Definitions » EPS (Diluted)

Mangoceuticals (Mangoceuticals) EPS (Diluted) : $-0.47 (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mangoceuticals EPS (Diluted)?

Mangoceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.10. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.47.

Mangoceuticals's EPS (Basic) for the three months ended in Mar. 2024 was $-0.10. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.47.

Mangoceuticals's EPS without NRI for the three months ended in Mar. 2024 was $-0.10. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.47.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Mangoceuticals EPS (Diluted) Historical Data

The historical data trend for Mangoceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mangoceuticals EPS (Diluted) Chart

Mangoceuticals Annual Data
Trend Dec21 Dec22 Dec23
EPS (Diluted)
- -0.13 -0.57

Mangoceuticals Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 -0.14 -0.11 -0.12 -0.10

Competitive Comparison of Mangoceuticals's EPS (Diluted)

For the Health Information Services subindustry, Mangoceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mangoceuticals's PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Mangoceuticals's PE Ratio falls into.



Mangoceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Mangoceuticals's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.212-0)/16.113
=-0.57

Mangoceuticals's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.368-0)/22.833
=-0.10

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mangoceuticals  (NAS:MGRX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Mangoceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Mangoceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Mangoceuticals (Mangoceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15110 N. Dallas Parkway, Suite 600, Dallas, TX, USA, 75248
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED product.
Executives
Amanda Elizabeth Hammer officer: Chief Operating Officer 5128 GADSDEN AVENUE, KELLER TX 76244
Jacob D. Cohen director, 10 percent owner, officer: CEO 2101 GLENDALE DRIVE, PLANO TX 75023
Tiger Cub Trust 10 percent owner 19 RYDDINGTON PL, DALLAS TX 75230
Kenny Myers director 5101 ADDISON CIRCLE,, UNIT 401,, ADDISON TX 75001
Lorraine Pamela D'alessio director 8200 WILSHIRE BLVD, BEVERLY HILLS, CALIFORNIA CA 90211
Eugene M Johnston officer: CFO PO BOX 669047, CHARLOTTE NC 28266
Jonathan Arango director, officer: President, COO and Secretary 15110 DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Alex P. Hamilton director 26 LOOP ROAD, BEDFORD NY 10506